Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products
Vancouver, British Columbia--(Newsfile Corp. - April 20, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today launched its Ibogaine Initiative, a program to extend the Company's Health Canada-licensed GMP platform to include the manufacture and supply of ibogaine. The initiative comes as the United States has, for the first time, taken ini
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-04-20 6:00 AM EDT | Optimi Health Corp.
Optimi Health startet Ibogaine-Initiative, da US-Executive Order einen Weg für psychedelische Arzneimittelprodukte signalisiert
Vancouver, British Columbia--(Newsfile Corp. - Montag, 20. April 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (das "Unternehmen" oder "Optimi"), ein kommerziell tätiger pharmazeutischer Hersteller regulierter psychedelischer Arzneimittelprodukte, gab heute den Start seiner Ibogaine-Initiative bekannt. Ziel des Programms ist es, die nach GMP lizenzierte Plattform des Unternehmens mit Health-Canada-Zulassung auf die Herstellung und Lieferung von Ibogaine auszuwe
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-04-20 2:00 AM EDT | Optimi Health Corp.
Unbuzzd Wellness Announces Resignation of Chief Executive Officer
Vancouver, British Columbia--(Newsfile Corp. - April 17, 2026) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd™,the scientifically-proven beverage proven to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms, announces today that John Duffy has resigned from his position as Chief Executive Officer of the Company, effective as of the date hereof. The Company thanks Mr. Duffy for his contributions and wi
2026-04-17 5:00 PM EDT | Unbuzzd Wellness Inc.
PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery
Toronto, Ontario--(Newsfile Corp. - April 16, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on microneedle patch technologies and peptide-enabled product oppor
Biotechnologies, Pharmaceutique
2026-04-16 8:00 AM EDT | PharmaTher Holdings Ltd.
Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation
Ontario and Chicago, Illinois--(Newsfile Corp. - April 15, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today provided an operational business update on the ongoing commercialization of GRAFAPEX™ (treosulfan) for Injection in the United States and on certain recent capital allocation and capital structure developments and announced company management's participation in two upcoming investor conferences. All dollar amounts in this news release are in US dollars unle
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-15 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Patient Safety Must Remain the Foundation of Scope of Practice Decisions in Canada
Ottawa, Ontario--(Newsfile Corp. - April 15, 2026) - As scope of practice expansion is actively being considered across Canada, the Canadian Ophthalmological Society (COS) is emphasizing that patient safety must remain the central and non-negotiable principle guiding any changes to healthcare delivery. While COS supports innovation and system modernization, it is deeply concerned that several proposed changes would expand independent clinical authority to non-physician providers without
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-15 12:05 PM EDT | Canadian Ophthalmological Society (COS)
La sécurité des patients doit demeurer le fondement des décisions relatives au champ de pratique au Canada
Ottawa, Ontario--(Newsfile Corp. - 15 avril 2026) - Alors que l'élargissement des champs de pratique est activement envisagé à travers le Canada, la Société canadienne d'ophtalmologie (SCO) rappelle que la sécurité des patients doit demeurer le principe central et non négociable guidant toute évolution de la prestation des soins de santé. Bien que la SCO appuie l'innovation et la modernisation du système, elle demeure profondém
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-15 12:05 PM EDT | Canadian Ophthalmological Society (COS)
Yellowbird Diagnostics Announces First Patients Dosed in Phase 1 Trial of NeuCavis(TM)
Ottawa, Ontario--(Newsfile Corp. - April 15, 2026) - Yellowbird Diagnostics Inc. today announced the successful dosing and imaging of the first participants in its Phase I clinical trial of NeuCaVis™, a novel metabolic PET imaging agent desig
Biotechnologies, Pharmaceutique
2026-04-15 7:15 AM EDT | Yellowbird Diagnostics
Jones Healthcare Group's Near-Term Emissions Reduction Targets Validated by the Science Based Targets Initiative
London, Ontario--(Newsfile Corp. - April 14, 2026) - Jones Healthcare Group's near-term greenhouse gas emissions reduction targets have been approved by the Science Based Targets initiative (SBTi), marking a significant step in the company's commitment to reducing emissions across its operations and broader value chain. As part of its validated targets, Jones commits to reduce absolute scope 1 and scope 2 greenhouse gas emissions 43.26% by 2030 from a 2023 base year. The company also c
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-14 10:00 AM EDT | Jones Healthcare Group
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
Encinitas, California--(Newsfile Corp. - April 14, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the publication of the results from its Phase 1 ABACUS-1 study of KIO-301 in Nature Medicine. The publication adds clinical detail to a program aimed at restoring light responsiveness with a small molecule "photoswitch" in patients with the advanced inherited retinal disease, retinitis pigmentosa. The publication
Biotechnologies, Pharmaceutique
2026-04-14 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Telescope Innovations Provides Financial Results of Second Fiscal Quarter 2026
Vancouver, British Columbia--(Newsfile Corp. - April 13, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a developer of advanced technologies and services for the global pharmaceutical and chemical industries, reports financial results for the fiscal quarter ended February 28, 2026 (Q2 FY2026). The Company generated revenues of approximately $1.6 million during this period, with strong contributions from the development a
Technologies, Produits chimiques, Pharmaceutique
2026-04-13 6:00 PM EDT | Telescope Innovations Corp.
PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology
Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, announced it has submitted U.S. provisional patent application No. 64/0
Biotechnologies, Pharmaceutique
2026-04-13 8:00 AM EDT | PharmaTher Holdings Ltd.
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study
Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses has demonstrated a complete response of all animals treated with X-Ray-activated Rutherrin® in a preclinical animal model of M
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-04-13 7:00 AM EDT | Theralase Technologies Inc.
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - April 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using it
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-13 7:00 AM EDT | Phio Pharmaceuticals Corp.
Theralase(R) Closes $CAN 2.66 Million Financing
Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has successfully closed both a non-brokered private placement offering ("Offering
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-04-10 7:00 AM EDT | Theralase Technologies Inc.
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - April 9, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Robert Bitterman, Chief Executive Officer and Chairman of the Board, will present at the Centri Capital Conference on Tuesday, April 14, 2026, at Nasdaq Marketsite in New York City. The present
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-09 7:00 AM EDT | Phio Pharmaceuticals Corp.
BioOra and Octane Biotech Sign Letter of Intent to Expand Cell Therapy Manufacturing Using the Cocoon(R) Platform
New Zealand and Kingston, Ontario--(Newsfile Corp. - April 7, 2026) - BioOra Limited ("BioOra"), a commercial-stage cell therapy company advancing CAR-T therapies for cancer patients, and Octane Biotech Inc., an Octane Medical Group Company ("Octane"), today announced the signing of a Letter of Intent (LOI) to collaborate on the co-development and deployment of advanced cell therapies using the Cocoon® automated cell therapy manufacturing platform. The collaboration bui
Biotechnologies, Pharmaceutique
2026-04-07 10:15 AM EDT | Octane Medical Group
Canadian Ophthalmologists Highlight Seasonal Environmental Risks to Eye Health
Ottawa, Ontario--(Newsfile Corp. - April 7, 2026) - Ophthalmologists across Canada are observing the impact of seasonal environmental exposures — including ultraviolet (UV) radiation, wildfire smoke, and airborne allergens — on patients' ocular health and visual comfort. As these factors intensify during the spring and summer months, the Canadian Ophthalmological Society (COS) is underscoring the importance of awareness and preventive care to reduce both immediate irritation and l
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-07 7:30 AM EDT | Canadian Ophthalmological Society (COS)
Les ophtalmologistes canadiens mettent en garde contre les risques environnementaux saisonniers pour la santé oculaire
Ottawa, Ontario--(Newsfile Corp. - 7 avril 2026) - Partout au pays, les ophtalmologistes constatent les effets des expositions environnementales saisonnières, notamment le rayonnement ultraviolet (UV), la fumée des feux de forêt et les allergènes en suspension dans l'air - sur la santé oculaire et le confort visuel des patients. À mesure que ces facteurs s'intensifient au printemps et à l'été, la Société canadienne d'ophtalmologie (SCO) s
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-07 7:30 AM EDT | Canadian Ophthalmological Society (COS)
Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors
Encinitas, California--(Newsfile Corp. - April 7, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (the "Company"), today announced that it has closed on a private placement providing up to $24 million in gross proceeds, consisting of $5.0 million in upfront funding and up to an additional $19 million upon the exercise of accompanying milestone-based warrants. The sole investors in the private placement are Perceptive Advisors and ADAR1 Capital Management. No placement agent was engaged in
Biotechnologies, Pharmaceutique
2026-04-07 7:00 AM EDT | Kiora Pharmaceuticals, Inc.